Ambeed.cn

首页 / / / / LY456236

LY456236 {[allProObj[0].p_purity_real_show]}

货号:A243293 Ambeed 开学季,买赠积分,赢豪礼

LY 456236 HCl is a selective mGlu1 receptor antagonist (IC50 values are 143 nM and > 10 μM for mGlu1 and mGlu5 receptors respectively).

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
LY456236 化学结构 CAS号:338736-46-2
LY456236 化学结构
CAS号:338736-46-2
LY456236 3D分子结构
CAS号:338736-46-2
LY456236 化学结构 CAS号:338736-46-2
LY456236 3D分子结构 CAS号:338736-46-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

LY456236 纯度/质量文件 产品仅供科研

货号:A243293 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 EGFR/ErbB1 ErbB3 ErbB4 HER2/ErbB2 mutant EGFR 其他靶点 纯度
WZ-3146 ++++

EGFR (E746_A750/T790M), IC50: 14 nM

EGFR (E746_A750), IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
Daphnetin +

EGFR, IC50: 7.67 μM

PKA,PKC {[allProObj[0].p_purity_real_show]}
Lifirafenib ++

EGFR, IC50: 29 nM

+

EGFR(T790M/L858R), IC50: 495 nM

{[allProObj[0].p_purity_real_show]}
PD168393 ++++

EGFR, IC50: 0.70 nM

{[allProObj[0].p_purity_real_show]}
Nazartinib ++

mutant EGFR, Ki: 0.031 μM

++

mutant EGFR, Ki: 0.031 μM

{[allProObj[0].p_purity_real_show]}
Norcantharidin {[allProObj[0].p_purity_real_show]}
CL-387785 ++++

EGFR, IC50: 370 pM

{[allProObj[0].p_purity_real_show]}
WHI-P154 +++

EGFR, IC50: 4 nM

Src,VEGFR {[allProObj[0].p_purity_real_show]}
Tyrphostin A9 +

EGFR, IC50: 460 μM

PDGFR {[allProObj[0].p_purity_real_show]}
AG 555 +

EGFR, IC50: 0.7 μM

{[allProObj[0].p_purity_real_show]}
AG 494 +

EGFR, IC50: 1.2 μM

{[allProObj[0].p_purity_real_show]}
AG-556 +

EGFR, IC50: 5 μM

{[allProObj[0].p_purity_real_show]}
RG13022 +

EGFR, IC50: 4 μM

{[allProObj[0].p_purity_real_show]}
Tyrphostin RG 14620 {[allProObj[0].p_purity_real_show]}
Vandetanib +

EGFR, IC50: 500 nM

{[allProObj[0].p_purity_real_show]}
CNX-2006 ++

mutant EGFR, IC50: <20 nM

++

mutant EGFR, IC50: <20 nM

{[allProObj[0].p_purity_real_show]}
AZD3759 ++++

EGFR (L858R), IC50: 0.2 nM

EGFR (WT), IC50: 0.3 nM

{[allProObj[0].p_purity_real_show]}
Erlotinib ++++

EGFR, IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
Saracatinib +++

EGFR (L861Q), IC50: 4 nM

EGFR, IC50: 5 nM

{[allProObj[0].p_purity_real_show]}
AG1557 {[allProObj[0].p_purity_real_show]}
Rociletinib ++

EGFR (wt), Ki: 303.3 nM

EGFR (L858R/T790M), Ki: 21.5 nM

{[allProObj[0].p_purity_real_show]}
AG490 +

EGFR, IC50: 0.1 μM

{[allProObj[0].p_purity_real_show]}
Cetuximab ++++

EGFR, Kd: 0.39 nM

{[allProObj[0].p_purity_real_show]}
Osimertinib ++

WT EGFR, IC50: 12.92 nM

L858R/T790M EGFR, IC50: 11.44 nM

{[allProObj[0].p_purity_real_show]}
Osimertinib mesylate {[allProObj[0].p_purity_real_show]}
Chrysophanol mTOR {[allProObj[0].p_purity_real_show]}
PD153035 ++++

EGFR, Ki: 5.2 pM

{[allProObj[0].p_purity_real_show]}
Olmutinib BTK {[allProObj[0].p_purity_real_show]}
WZ4002 ++++

EGFR (L858R/T790M), IC50: 8 nM

EGFR (L858R), IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
Icotinib +++

EGFR, IC50: 5 nM

{[allProObj[0].p_purity_real_show]}
Desmethyl Erlotinib HCl ++++

EGFR, IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
Cyasterone {[allProObj[0].p_purity_real_show]}
PP 3 +

EGFR tyrosine kinase, IC50: 2.7 μM

{[allProObj[0].p_purity_real_show]}
WZ8040 {[allProObj[0].p_purity_real_show]}
(-)-Epigallocatechin Gallate {[allProObj[0].p_purity_real_show]}
AG 18 +

EGFR, IC50: 35 μM

{[allProObj[0].p_purity_real_show]}
O-Desmethyl gefitinib ++

EGFR, IC50: 36 nM

{[allProObj[0].p_purity_real_show]}
Falnidamol {[allProObj[0].p_purity_real_show]}
AZ-5104 ++++

EGFR (L861Q) , IC50: <1 nM

EGFR (L858R), IC50: 6 nM

+++

ErbB4, IC50: 7 nM

BRK {[allProObj[0].p_purity_real_show]}
Butein {[allProObj[0].p_purity_real_show]}
Genistein {[allProObj[0].p_purity_real_show]}
SU5214 +

EGFR, IC50: 36.7 μM

{[allProObj[0].p_purity_real_show]}
Naquotinib {[allProObj[0].p_purity_real_show]}
Gefitinib ++

EGFR, IC50: 15.5 nM

+

EGFR (858R/T790M), IC50: 823.3 nM

{[allProObj[0].p_purity_real_show]}
Theliatinib +++

WT EGFR, IC50: 3 nM

++

EGFR T790M/L858R, IC50: 22 nM

{[allProObj[0].p_purity_real_show]}
Lazertinib ++++

WT EGFR, IC50: 76 nM

L858R/T790M EGFR, IC50: 2 nM

++++

Del19/T790M, IC50: 1.7 nM

{[allProObj[0].p_purity_real_show]}
Gefitinib-based PROTAC 3 ++

EGFR, DC50: 22.3 nM

{[allProObj[0].p_purity_real_show]}
MTX-211 PI3K {[allProObj[0].p_purity_real_show]}
(E)-AG 99 {[allProObj[0].p_purity_real_show]}
Licochalcone D PARP,Caspase {[allProObj[0].p_purity_real_show]}
Zipalertinib +++

EGFR (L861Q), IC50: 4.1 nM

EGFR WT, IC50: 8 nM

+++

HER4, IC50: 4 nM

++++

EGFR(d746-750), IC50: 1.4 nM

EGFR L858R, IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
JND3229 +++

EGFR WT, IC50: 6.8 nM

++

EGFR L858R/T790M, IC50: 30.5 nM

{[allProObj[0].p_purity_real_show]}
Firmonertinib mesylate {[allProObj[0].p_purity_real_show]}
Tyrphostin AG30 {[allProObj[0].p_purity_real_show]}
EGFR-IN-12 ++

EGFR, IC50: 21 nM

{[allProObj[0].p_purity_real_show]}
Mobocertinib {[allProObj[0].p_purity_real_show]}
(Rac)-JBJ-04-125-02 {[allProObj[0].p_purity_real_show]}
(S)-Sunvozertinib {[allProObj[0].p_purity_real_show]}
BLU-945 {[allProObj[0].p_purity_real_show]}
Poziotinib +++

HER1, IC50: 3.2 nM

++

HER4, IC50: 23.5 nM

+++

HER2, IC50: 5.3 nM

{[allProObj[0].p_purity_real_show]}
TAK-285 ++

EGFR/HER1, IC50: 23 nM

+

HER4, IC50: 260 nM

++

HER2, IC50: 17 nM

{[allProObj[0].p_purity_real_show]}
ARRY-380 analog {[allProObj[0].p_purity_real_show]}
Canertinib ++++

EGFR, IC50: 1.5 nM

+++

ErbB2, IC50: 9.0 nM

{[allProObj[0].p_purity_real_show]}
Dacomitinib +++

EGFR, IC50: 6.0 nM

+

ErbB4, IC50: 73.7 nM

+

ErbB2, IC50: 45.7 nM

{[allProObj[0].p_purity_real_show]}
EGFR/ErbB-2/ErbB-4 inhibitor-2 +

ErbB4, IC50: 1.91 μM

+

ErbB2, IC50: 0.08 μM

{[allProObj[0].p_purity_real_show]}
(E/Z)-CP-724714 ++

HER2/ErbB2, IC50: 10 nM

{[allProObj[0].p_purity_real_show]}
Lapatinib ++

EGFR, IC50: 10.8 nM

+

ErbB4, IC50: 367 nM

+++

ErbB2, IC50: 9.2 nM

{[allProObj[0].p_purity_real_show]}
AEE788 ++++

EGFR, IC50: 2 nM

+

HER4/ErbB4, IC50: 160 nM

+++

HER2/ErbB2, IC50: 6 nM

c-Fms {[allProObj[0].p_purity_real_show]}
AV-412 free base ++++

EGFR, IC50: 0.75 nM

++

ErbB2, IC50: 19 nM

++++

EGFRL858R/T790M, IC50: 0.51 nM

EGFRT790M, IC50: 0.79 nM

{[allProObj[0].p_purity_real_show]}
Neratinib +

EGFR, IC50: 92 nM

+

HER2, IC50: 59 nM

Src {[allProObj[0].p_purity_real_show]}
BMS-599626 ++

HER1, IC50: 20 nM

+

HER4, IC50: 190 nM

++

HER2, IC50: 30 nM

{[allProObj[0].p_purity_real_show]}
Tucatinib +++

ErbB2, IC50: 8 nM

{[allProObj[0].p_purity_real_show]}
Allitinib ++++

EGFR, IC50: 0.5 nM

++++

ErbB4, IC50: 0.8 nM

+++

ErbB2, IC50: 3.0 nM

{[allProObj[0].p_purity_real_show]}
Pelitinib +

EGFR, IC50: 38.5 nM

+

ErbB2, IC50: 1.255 μM

Src,Raf {[allProObj[0].p_purity_real_show]}
Sapitinib +++

EGFR, IC50: 4 nM

+++

ErbB3, IC50: 4 nM

+++

ErbB2, IC50: 3 nM

{[allProObj[0].p_purity_real_show]}
CUDC-101 +++

EGFR, IC50: 2.4 nM

++

HER2, IC50: 15.7 nM

HDAC {[allProObj[0].p_purity_real_show]}
Varlitinib +++

ErbB1, IC50: 7 nM

++++

ErbB2, IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
Afatinib dimaleate ++++

EGFR (L858R/T790M), IC50: 0.4 nM

EGFR (wt), IC50: 0.5 nM

++

HER2, IC50: 14 nM

{[allProObj[0].p_purity_real_show]}
Canertinib dihydrochloride +++

EGFR, IC50: 7.4 nM

+++

ErbB2, IC50: 9 nM

{[allProObj[0].p_purity_real_show]}
Allitinib tosylate ++++

EGFR (T790M/L858R), IC50: 12 nM

EGFR, IC50: 0.5 nM

++++

ErbB4, IC50: 0.8 nM

+++

ErbB2, IC50: 3.0 nM

{[allProObj[0].p_purity_real_show]}
Tyrphostin AG 528 +

EGFR, IC50: 4.9 μM

+

HER2, IC50: 2.1 μM

{[allProObj[0].p_purity_real_show]}
Afatinib ++++

EGFR (wt), IC50: 0.5 nM

EGFR (L858R), IC50: 10 nM

++++

ErbB4, IC50: 1 nM

++

HER2, IC50: 14 nM

{[allProObj[0].p_purity_real_show]}
Pyrotinib dimaleate ++

EGFR, IC50: 0.013 μM

++

HER2, IC50: 0.038 μM

{[allProObj[0].p_purity_real_show]}
Epertinib HCl ++++

EGFR, IC50: 1.48 nM

+++

HER4, IC50: 2.49 nM

+++

HER2, IC50: 7.15 nM

{[allProObj[0].p_purity_real_show]}
Tuxobertinib ++++

EGFR, Kd: 0.2 nM

++++

HER2, Kd: 0.76 nM

{[allProObj[0].p_purity_real_show]}
ALK-IN-1 ++

EGFR(C797S/del19), IC50: 138.6 nM

EGFR(del19), IC50: 36.8 nM

ALK {[allProObj[0].p_purity_real_show]}
Brigatinib +

EGFR(del19), IC50: 39.9 nM

EGFR(C797S/T790M/del19), IC50: 67.2 nM

FLT3,ALK {[allProObj[0].p_purity_real_show]}
Avitinib ++++

EGFR L858R/T790M, IC50: 0.18 nM

BTK {[allProObj[0].p_purity_real_show]}
EAI045 {[allProObj[0].p_purity_real_show]}
Almonertinib {[allProObj[0].p_purity_real_show]}
BI-4020 ++++

EGFRdel19 T790M C797S, IC50: 0.2 nM

{[allProObj[0].p_purity_real_show]}
EGFR-IN-7 ++++

EGFRL858R/T790M, IC50: 0.19 nM

EGFRd746-750/T790M/C797S, IC50: 0.26 nM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

LY456236 生物活性

描述 LY 456236 hydrochloride is a selective mGlu1 receptor antagonist (IC50 values are 143 nM and > 10 μM for mGlu1 and mGlu5 receptors respectively).

LY456236 参考文献

[1]Shannon HE, Peters SC, et al. Anticonvulsant effects of LY456236, a selective mGlu1 receptor antagonist. Neuropharmacology. 2005;49 Suppl 1:188-95.

LY456236 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.15mL

0.63mL

0.31mL

15.73mL

3.15mL

1.57mL

31.47mL

6.29mL

3.15mL

LY456236 技术信息

CAS号338736-46-2
分子式C16H16ClN3O2
分子量 317.77
别名
运输蓝冰
存储条件

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 250 mg/mL(786.73 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。